Table 1. Patient characteristics.

Parameter	Patients
Epidemiology
Patients n	215
Gender, m/f (%)	171/44 (79.5/20.5)
Age, median, range	64 (38–86)
Etiology of liver disease
Alcohol abuse, n (%)	73 (34.9%)
Hepatitis C, n (%)	83 (38.6%)
Hepatitis B, n (%)	40 (18.6%)
NASH1, n (%)	17 (7.9%)
Cryptogenic, n (%)	15 (7.0%)
Autoimmune, n (%)	1 (0.5%)
BCLC stage2
A, n (%)	43 (20.0%)
B, n (%)	89 (41.4%)
C, n (%)	70 (32.6%)
D, n (%)	13 (6.0%)
Child-Pugh score
A, n (%)	133 (61.9%)
B, n (%)	63 (29.3%)
C, n (%)	19 (8.8%)
Albumin-Bilirubin (ALBI) grade
1, n (%)	77 (35.8%)
2, n (%)	105 (48.8%)
3, n (%)	32 (14.9%)
CLIP3 Score
>2, n (%)	104 (48.4%)
MELD4, median, range	10 (6–36)
Treatment
Resection, n (%)	26 (12.1%)
Local ablation*, n (%)	122 (56.7%)
Sorafenib, n (%)	54 (25.1%)
Liver transplantation, n (%)	19 (8.8%)
Laboratory results
Sodium (mmol/l), median, range	139, 116–148
ALT5 (U/l), median, range	56, 7–2131
AST6 (U/l), median, range	83, 20–2120
GGT7 (U/l), median, range	184, 10–2201
ALP8 (U/l), median, range	140, 43–937
Bilirubin (mg/dl), median, range	1.1, 0.2–20.0
Albumin (mg/dl), median, range	3.6, 2–5.0
INR9, mean, median, range	1.20, 0.89–3.03
Creatinine (mg/dl), median, range	0.88, 0.11–5.20
CRP10 (mg/dl), median, range	0.88, 0.02–34.73
AFP11 (ng/ml), median, range	28.6, 1.4–60500

*including Transarterial chemoembolisation (TACE), Radiofrequency ablation (RFA), Laser interstitial thermal therapy (LITT).

Abbreviations:

¹NASH, non-alcoholic steatohepatitis;

²BCLC, Barcelona liver clinic;

³CLIP, Cancer of the Liver Italian Program;

⁴MELD, model of end stage liver disease;

⁵ALT, alanine aminotransferase,

⁶AST, aspartate aminotransferase;

⁷GGT, gamma-glutaryl-transferase;

⁸ALP, alkaline phosphatase;

⁹INR, internationalized ratio;

¹⁰CRP, C-reactive protein;

¹¹AFP, alpha-Fetoprotein